| Trial ID: | L1904 |
| Source ID: | NCT02752880
|
| Associated Drug: |
Yh1 Group
|
| Title: |
YH1 in Poorly Controlled Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02752880/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: YH1 group|DRUG: placebo group
|
| Outcome Measures: |
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks, The primary efficacy endpoint was the percentage change in HbA1c levels from baseline to 12 weeks. The HbA1c level was measured by HPLC in the Department of Laboratory Medicine at Chang Gung Memorial Hospital., 12 weeks | Secondary: The Percentage Change in 2hPG From Baseline to Week 12, The secondary efficacy endpoint was the percentage change in 2hPG level from baseline to 12 weeks by using enzymatic method in the Department of Laboratory Medicine at Chang Gung Memorial Hospital., 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Chang Gung Memorial Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
46
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-06
|
| Completion Date: |
2018-02
|
| Results First Posted: |
2019-07-22
|
| Last Update Posted: |
2019-07-22
|
| Locations: |
Taoyuan, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT02752880
|
